![]() ![]() Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. pmid:24054399Ĭhow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. pmid:19532139Ĭhoi BD, Suryadevara CM, Gedeon PC, Nd HJ, Sanchezperez L, Bigner DD, et al. Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. 1997 315(7109):629.Īhmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Bias in meta-analysis detected by a simple, graphical test. Aggregate data meta-analysis with time-to-event outcomes. Williamson PR, Smith CT, Hutton JL, Marson AG. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Update of the stroke therapy academic industry roundtable preclinical recommendations. ![]() 2017 1:7.įisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. Driving gene-engineered T cell immunotherapy of cancer. If the efficacy of different doses of CAR T cells were evaluated, all the valid hazard ratios for survival would be extracted. When different CAR T cells were evaluated in multiple groups in one publication, the data in each group were extracted as an individual experiment for analysis. If there was no reply or no useful information, Engauge Digitizer software V9.7 for macOS 10.12.3 was used to measure graphically the data as presented. When the data was reported merely in image format, we attempted to contact the correspondence author of the publication to ask for the original data. We extracted the following information from the reports: first-author year of publication animal species age experimental group control group animal number type of model target the generation of CAR the type of cancer the Kaplan-Meier survival curve. We identified all the studies with the first author and the year of publication. Three reviewers (YW, RX, and KJ) independently extracted data with a extraction form, and we checked all the data very carefully. Also, we attempted to explore the experimental design features of current studies in order to point out the possible shortcomings of the preclinical experimental designs and the future clinical trials. Here, we conducted a meta-analysis of animal models in order to evaluate the potential value of CAR-T therapy for solid tumors based on the preclinical trials. Which target of CARs will induce better or worse outcomes? What is the role of CARs in treating different types of cancer? Are the outcomes reliable in preclinical studies? These questions still remain unknown. ![]() However, an evaluation of the effects of preclinical studies remains absent. Most recently, publications on preclinical trials of solid tumors have abounded, and relevant phase I or phase I/II clinical trials have just been initiated. At present, more and more scientists are devoted to searching for potential targets. So far, an increasing number of preclinical trials have focused on solid tumors, targeting at carcinoembryonic antigen (CEA), interleukin 13 receptor (IL-13R), human epidermal growth factor receptor 2 (HER2), fibroblast activation protein (FAP) and so on. In the field of hematologic malignancies, the surging of CAR immunotherapy has demonstrated remarkable success.Ĭompared with hematologic malignancies, solid tumors remained a significant challenge to CAR-T immunotherapy. CARs can target specific antigen of tumor cells, therefore activating T cells and inducing robust antitumor effects. However, the leaps and bounds of chimeric antigen receptor (CAR) immunotherapy is changing such a situation. Cancer is one of the leading causes of death around the world. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |